We hypothesize that the beneficial effect of EET-agonists on cardiac function is mediated by a reduction in the local secretion of inflammatory molecules such as NOV by pericardial fat, accompanied by upregulation of PGC-1α and HO-1 and amelioration of obesity-mediated cardiomyopathy. Here, HMOX1 is linked to Obesity.